Subchorionic hematoma: Research status and pathogenesis (Review).

Subchorionic hematoma (SCH) is a hematoma in which blood accumulates between the chorion and decidua basalis due to the separation of the chorion and decidua basalis. It is common in patients with threatened abortion in early pregnancy and is mainly detected by ultrasound. SCH mainly manifests as an hypoechoic or anechoic crescent-shaped fluid dark area on ultrasound images.

Analysis of risk factors and pregnancy outcomes in pregnant women with subchorionic hematoma.

Subchorionic hemorrhage (SCH) or hematoma is one of the abnormal ultrasonic manifestations. At present, there are few studies on the pathogenesis of SCH, and its underlying mechanism is still unclear. It may be related to abnormal placenta formation and implantation, autoimmune dysfunction, and coagulation dysfunction.

Dynamic Evaluation of the Rectus Abdominis Muscle before and after Delivery by Ultrasonography.

Objective: To evaluate the changes of rectus abdominis thickness and inter-rectus distance before and after delivery with high-frequency ultrasound.

Methods: A total of 148 pregnant women at 12 weeks of gestation who underwent prenatal examination in our hospital from January 2019 to March 2020 were selected, and 140 of them cooperated with rectus abdominis examination. According to the results of rectus abdominis examination 42 days after delivery, 97 patients were divided into the DRA group with rectus abdominis isolated and 43 patients were divided into the normal group with rectus abdominis not isolated.

Effects of elevated bile acid levels on fetal myocardium in intrahepatic cholestasis of pregnancy, a retrospective study from a neonatal perspective.

Aim: Intrahepatic cholestasis of pregnancy (ICP) is a liver disease which may lead to a sudden fetal death.Previous studies have suggested that the fetal accident may be related to their cardiac dysfunction.However,the relationship between fetal cardiac dysfunction and their maternal bile acid levels is not clear.

[Clinical study of combined treatment of remifemin and paroxetine for perimenopausal depression].

Objective: To explore the efficacies and safety of combined treatment of remifemin and paroxetine for perimenopausal depression.

Methods: A total of 120 patients with perimenopausal depression were digital randomly divided into the treatment and control groups (n = 60 each). The treatment group received oral remifemin one tablet twice daily and paroxetine 20 mg once daily for 2 months while the control group oral paroxetine 20 mg once daily for 2 months.